Insulet Corporation (PODD) News
Follow Insulet Corporation (PODD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 36 public stories across 24 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Insulet launches Omnipod Discover in the U.S.
Insulet announced that Omnipod Discover is now available in the United States.
EQUITY | Oct 12, 2026, 11:03 AM UTC
H
Insulet Reports Q2 2026 Results: Full Earnings Call Transcript
Insulet (NASDAQ: PODD ) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered APIs. For comprehensive financial data and transcrip
LIVE | Oct 08, 2026, 08:01 AM UTC
M
Insulet to announce Q3 2026 results Nov. 4
Insulet said it will announce third-quarter 2026 financial results on November 4, 2026.
EQUITY | Oct 01, 2026, 11:10 AM UTC
L
Weekly Recap: Refinancing, revolver boost and Type 2 mix, early retention
Insulet Corporation (NASDAQ:PODD) refinanced $475M of term debt, cut margins ~25bps and expanded a $750M revolver, while rolling out Gen—2 Omnipod5/Libre3 Plus and planning Omnipod6 (2027) and a Type 2 closed—loop pivota
NEWS | Sep 28, 2026, 11:06 AM UTC
M
Insulet refinances $475M term loans, expands revolver to $750M
Insulet entered a Ninth Amendment to its Credit Agreement to refinance $475 million of term loans and increase revolving commitments to $750 million. The new term loans feature margins of 0.75% for base rate and 1.75% fo
EQUITY | Sep 21, 2026, 09:14 PM UTC
L
PODD - Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors — 3rd Annual Healthcare Forum
PODD - Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors — 3rd Annual Healthcare Forum
NEWS | Sep 18, 2026, 11:07 AM UTC
H
Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus
Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets.On Friday, the Do
NEWS | Sep 13, 2026, 01:11 PM UTC
L
Insulet board members Scannell and Minogue to step down
Timothy J. Scannell and Michael R. Minogue notified Insulet they will leave the board, effective Sept. 3, 2026 and Sept. 15, 2026, respectively. The item cites an 8-K filing dated Sep. 10, 2026.
EQUITY | Sep 10, 2026, 08:15 PM UTC
H
PODD: Growth moderates as type 2 retention challenges are addressed and new innovations launch
Guidance was lowered due to higher attrition in type 2 diabetes, but corrective actions and a robust innovation pipeline are expected to drive future growth. U.S. and international growth rates will moderate, with stable
EQUITY | Sep 09, 2026, 08:15 PM UTC
M
PODD lowered guidance on higher type 2 attrition
PODD said it lowered guidance due to higher attrition in type 2 diabetes and softer new starts. The company cited corrective actions and innovations underway, expecting growth to moderate with stable pricing and continue
EQUITY | Sep 09, 2026, 07:33 PM UTC
L
PODD - Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
PODD - Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
EQUITY | Aug 26, 2026, 11:03 AM UTC
M
Insulet CEO Ashley McEvoy reports Form 4P transaction
Insulet Corp President and CEO Ashley McEvoy reported a Form 4P filing showing 1,100 shares at $147.47 for $162,217.
REGULATION | Aug 24, 2026, 11:21 AM UTC
L
PODD - Lost Money on Insulet Corporation (PODD)? A Class Action Suit is Seeking Recovery - Contact SueWallSt
PODD - Lost Money on Insulet Corporation (PODD)? A Class Action Suit is Seeking Recovery - Contact SueWallSt
EQUITY | Aug 20, 2026, 05:04 PM UTC
H
Analysts Downgrade Multiple Stocks
Multiple stocks downgraded by analysts
EQUITY | Aug 06, 2026, 11:28 AM UTC
H
These Analysts Slash Their Forecasts On Insulet After Q2 Results
Insulet Corp. (NASDAQ: PODD ) on Wednesday posted upbeat second-quarter results but lowered its full-year revenue guidance. Adjusted earnings rose to $1.66 per share from $1.17 a year earlier, beating the analyst consens
EARNINGS | Aug 06, 2026, 11:28 AM UTC
H
Omnipod Sales Soar, But Insulet's Outlook Cut Sparks Stock Selloff
Insulet Corp. (NASDAQ: PODD ) stock traded lower Wednesday after the insulin pump maker reported second-quarter results that topped Wall Street expectations but lowered its full-year revenue guidance and issued third-qua
EARNINGS | Aug 05, 2026, 11:58 AM UTC
H
PODD - Insulet Reports Second Quarter 2026 Results
PODD - Insulet Reports Second Quarter 2026 Results
EARNINGS | Aug 05, 2026, 11:08 AM UTC
H
Insulet FY2026 Adj EPS expected to be more than $6.46 vs $6.43 Est; Lowers FY2026 Sales Guidance from $3.277B-$3.331B to $3.250B-$3.304B vs
Insulet (NASDAQ: PODD ) FY2026 expected to be more than $6.46 vs $6.43 Est. lowers FY2026 sales outlook from $3.277 billion-$3.331 billion to $3.250 billion-$3.304 billion vs $3.321 billion estimate.
EARNINGS | Aug 05, 2026, 11:05 AM UTC
H
Insulet Safety Issues Drop PODD 6%
PODD stock falls on safety concerns
EQUITY | Aug 04, 2026, 10:36 AM UTC
H
Insulet Corporation Faces Securities Fraud Class Action
Insulet Corporation faces securities fraud class action
EQUITY | Aug 03, 2026, 02:05 PM UTC
H
Insulet Sued for Securities Law Violations
Insulet faces securities law violations lawsuit
REGULATION | Aug 03, 2026, 08:37 AM UTC
H
Insulet Sued for Securities Law Violations
Insulet faces securities law violations lawsuit
EQUITY | Jul 31, 2026, 07:08 AM UTC
L
BBNX (Buy, $22 PT), DXCM (Buy, $96 PT), PODD (Neutral, $174 PT), TNDM (Neutral, $18 PT) resuming coverage in the Diabetes sector – initiate
BBNX (Buy, $22 PT), DXCM (Buy, $96 PT), PODD (Neutral, $174 PT), TNDM (Neutral, $18 PT) resuming coverage in the Diabetes sector – initiate MMED @ UBS
EQUITY | Jul 28, 2026, 11:50 AM UTC
L
PODD Initiated Neutral W/$174.00 PT at UBS
PODD Initiated Neutral W/$174.00 PT at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
PODD - PODD Class Reminder: Insulet Investors are Reminded of the Upcoming August 31 Deadline in the Filed Securities Fraud Class Action to
PODD - PODD Class Reminder: Insulet Investors are Reminded of the Upcoming August 31 Deadline in the Filed Securities Fraud Class Action to Recover Losses
EQUITY | Jul 28, 2026, 10:37 AM UTC
H
Insulet price target raised to $172 from $165 at Citi
Citi raised the firm's price target on Insulet to $172 from $165 and keeps a Neutral rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medtech stocks
EQUITY | Jul 08, 2026, 10:35 AM UTC
L
Evercore ISI Adjusts Price Target on Insulet to $180 From $200
() -- Insulet (PODD) has an average rating of buy and mean price target of $236.35, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firms in North A
EQUITY | Jul 06, 2026, 01:10 PM UTC
L
Attention Long-Term Shareholders of Insulet Corporation (NASDAQ: PODD); Navan, Inc. (NASDAQ: NAVN); Via Transportation, Inc. (NYSE: VIA); an
PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Insule
EQUITY | Jul 06, 2026, 11:52 AM UTC
L
Rosen Law Firm Urges Insulet Corporation (NASDAQ: PODD) Stockholders with Large Losses to Contact the Firm for Information About Their Right
Rosen Law Firm, a global investor ri
EQUITY | Jul 05, 2026, 06:45 PM UTC
L
PODD STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Insulet Corporation Investors with Substantial Losses Have Oppor
NEW YORK CITY, NY / / July 5, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-ri
REGULATION | Jul 05, 2026, 11:01 AM UTC
L
Pomerantz LLP Announces Class Action Litigation Filing Against Insulet Corporation – PODD
NEW YORK CITY, NY / / July 4, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against
EQUITY | Jul 04, 2026, 03:00 PM UTC
L
PODD Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Insulet Corporation
PODD Stockholder Alert: Shareholder Rights Law Firm Rob
REGULATION | Jul 03, 2026, 11:12 PM UTC
L
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with the Schall Law Firm
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with the Schall Law Firm
REGULATION | Jul 03, 2026, 08:41 PM UTC
L
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, July 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nat
EQUITY | Jul 03, 2026, 07:08 PM UTC
L
Grabar Law Office Investigates Claims on Behalf of Shareholders of Insulet Corporation (PODD)
Philadelphia, Pennsylvania--(. - July 3, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Insulet Corporation (NASDAQ: PODD). WHAT IS THIS INVESTIGATION
EQUITY | Jul 03, 2026, 05:32 PM UTC
L
FDA Classifies Insulet Omnipod Pods Recall As Class I Due To Serious Injury Risk; Insulet Reports 24 Serious Injuries, No Deaths From Omnipo
FDA Classifies Insulet Omnipod Pods Recall As Class I Due To Serious Injury Risk; Insulet Reports 24 Serious Injuries, No Deaths From Omnipod Pods Issue As Of May 20
REGULATION | Jul 02, 2026, 05:24 PM UTC